PMLiVE5d
Eli Lilly’s mirikizumab shows promise in phase 3 Crohn’s disease study
Eli Lilly has shared one-year histologic outcomes from a phase 3 study of its interleukin-23p19 antagonist mirikizumab in ...
PMLiVE5d
FDA advisory committee recommends Stealth’s elamipretide for Barth syndrome
A US Food and Drug Administration (FDA) panel of experts has voted in support of Stealth BioTherapeutics’ elamipretide for ...
PMLiVE6d
Pfizer shares positive phase 3 results for Talzenna combination in prostate cancer
Up to 20% of patients will develop metastatic castration-resistant disease within five to seven years of diagnosis ...
PMLiVE12d
J&J’s Erleada shows overall survival benefit in head-to-head prostate cancer study
Johnson & Johnson (J&J) has announced results from a real-world study comparing its Erleada (apalutamide) to Pfizer and ...
PMLiVE10d
Astellas and AviadoBio enter exclusive dementia gene therapy deal worth over $2bn
Astellas Pharma and AviadoBio have entered into an exclusive option and licence agreement worth over $2bn for an ...
PMLiVE12d
Navigating US payer evidence needs to optimise market access
What clinical and economic evidence do US payers prefer to drive formulary decisions? How can you optimise your chances of ...
PMLiVE9d
Merck and Astellas/Pfizer’s bladder cancer combination receives MHRA approval
Merck & Co’s – known as MSD outside the US and Canada – Keytruda (pembrolizumab) and Astellas/Pfizer’s Padcev (enfortumab vedotin) have been approved by the Medicines and Healthcare products ...
PMLiVE11d
Merck’s Keytruda shows promise as perioperative head and neck cancer treatment
Merck & Co – known as MSD outside the US and Canada – has shared positive results from a late-stage study of its anti-PD-1 therapy in head and neck cancer. The phase 3 KEYNOTE-689 trial has been ...
PMLiVE9d
Roche’s Itovebi combination granted FDA approval for advanced breast cancer
Roche’s PI3K inhibitor Itovebi (inavolisib) has been approved by the US Food and Drug Administration (FDA) as part of a combination treatment for advanced breast cancer. The drug has been authorised ...
PMLiVE13d
AbbVie shares promising late-stage results for Parkinson’s disease candidate tavapadon
AbbVie has shared positive top-line results from a late-stage study of its investigational Parkinson’s disease (PD) drug in adults. The phase 3 TEMPO-1 trial evaluated two fixed doses of the D1/D5 ...
PMLiVE16d
Researchers develop new approach to target cells affected by motor neurone disease
It is hoped that preventing healthy cells from reading the molecules’ messages could lead to safer and more effective gene therapies for MND, as well as other neurodegenerative diseases, including ...
PMLiVE10d
GSK’s RSV vaccine Arexvy shown to protect older adults across three seasons
GSK’s Arexvy has been shown to protect older adults against respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD) over three full RSV seasons. Results from the phase 3 ...